Singapore HSA and EBC-46: How the Health Products Act Treats Botanical Supplements

Botanical supplements like blushwood berry extract sit inside well-defined regulatory frameworks across Asia-Pacific, but the rules differ in detail from country to country. Singapore is one of the most carefully regulated supplement markets in the region, and the Health Sciences Authority (HSA) administers the Health Products Act and the Medicines Act in a way that shapes how EBC-46 supplements can be imported, sold, and labelled. This article explains, in neutral terms, how the HSA approaches plant-based supplements, what categories matter for blushwood berry products, and what informed buyers should know.

This is a regulatory overview, not legal advice. Anyone importing or selling supplements commercially in Singapore should work directly with HSA and a qualified local advisor.

Where botanical supplements sit in Singapore's regulatory map

Singapore's HSA classifies products into several categories: therapeutic products (registered pharmaceuticals), Chinese Proprietary Medicines (CPM), traditional medicines, and health supplements. Health supplements — the category most relevant to blushwood berry extract — are defined as products containing a vitamin, mineral, herb, amino acid, or similar substance intended to supplement the diet. The framework is described publicly on the HSA Health Supplements page, and dealers must comply with the requirements set out in the Health Products Act.

Health supplements in Singapore do not require pre-market approval in the way that pharmaceutical products do. Instead, the regime relies on dealer responsibility: the importer or seller is accountable for ensuring the product is safe, accurately labelled, and compliant with prohibited-substance lists and contaminant limits. HSA reserves the right to recall or restrict products that breach these standards, and conducts post-market surveillance on samples drawn from the local market.

What the dealer's licence framework requires

Anyone supplying health supplements as a business in Singapore needs to comply with the Health Products Act's general requirements. The framework asks dealers to maintain quality records, ensure the product carries no prohibited ingredients, comply with heavy-metal and microbiological contamination limits, and avoid making unauthorised therapeutic claims. Labels must be in English, must list active and inactive ingredients, and must include the manufacturer's name and address.

These are the same fundamentals that apply across most well-developed supplement frameworks worldwide: third-party batch testing, transparent ingredient disclosure, and a clear separation between supplement-tier nutritional claims and disease-treatment claims that would shift the product into the therapeutic category. For blushwood berry extract products, this means the labelling cannot suggest the supplement diagnoses, treats, cures, or prevents disease.

Blushwood berry extract within this framework

There is no Singapore-specific monograph for blushwood berry extract, so a dealer would supply it as a general botanical health supplement, demonstrating compliance with the contaminant and prohibited-substance lists. Quality-conscious suppliers — including Blushwood Health — typically meet these requirements by manufacturing in GMP- and ISO-certified facilities and publishing third-party batch results. Their independent batch testing through Eurofins Scientific (an ISO/IEC 17025:2017-accredited lab) covers heavy metals (arsenic, lead, cadmium, mercury) and microbiological safety (E. coli, Salmonella, yeast, mould), the same parameters Singapore's framework focuses on.

Buyers can review the published lab work on the Blushwood Health lab-tests page before making a purchase. This kind of transparent batch documentation is what lets a careful supplement dealer demonstrate compliance to a regulator anywhere in the region.

How HSA differs from neighbouring frameworks

Singapore's Health Products Act is closer in spirit to the U.S. dietary supplement framework (DSHEA) and Australia's listed-medicine regime than to the more pre-approval-heavy European pathway. There is no requirement for a clinical trial to support a basic nutritional claim, but the dealer must hold evidence that any specific claim is substantiated, and HSA can demand documentation at any time. This contrasts with Japan's Food with Function Claims (FFC) framework, which requires upfront notification and a published claim dossier, and South Korea's Health Functional Food framework, which separates generic functional ingredients from product-specific claims more strictly.

For consumers, the practical takeaway is that Singapore-purchased supplements must still meet defined quality and labelling standards, even though the products are not pre-approved. A reputable brand sold in Singapore will look very similar in documentation terms to a reputable brand sold in the U.S., U.K., or Australia: published certificates of analysis, GMP-manufactured, transparent extraction ratios, and conservative claims.

What buyers in Singapore should look for

Whether buying domestically or importing for personal use, a few practical checks help. The label should state the extraction ratio (for example, 10:1 whole-seed extract), the serving size, the full ingredient list, and the manufacturer's contact details. Independent batch certificates should be available on request or published online. The product should carry the standard supplement-disclaimer language indicating it is not intended to diagnose, treat, cure, or prevent any disease — that disclaimer is a marker of responsible labelling, not a warning sign.

If a brand's labelling makes specific therapeutic claims about cancer, infections, or other diseases, that should prompt caution. Such claims would, in Singapore, push the product into the therapeutic-product category and trigger HSA registration requirements that no dietary supplement can satisfy.

Citations

1. Singapore Health Sciences Authority — Health Supplements, accessed 2026.

2. HSA — Health Products Regulation Overview, 2026.

3. Blushwood Health — EBC-46 Independent Lab Tests, accessed 2026.

Related Articles

Read more on regional regulatory frameworks: Japan's PMDA and Food with Function Claims framework, and South Korea MFDS and the Health Functional Food framework.